Samaritan’s Amphocil Approved in Cyprus

November 9, 2007

Samaritan Pharmaceuticals’ European subsidiary has received marketing authorization for its HIV fungus drug Amphocil in Cyprus.

Eugene Boyle, Samaritan’s chief financial officer, said he anticipates sales of Amphocil to begin after the company establishes an official price with Cyprus’ Minister of Health.

Injectable Amphocil is a lipid form of amphotericin B indicated for the treatment of invasive aspergillosis, a life-threatening systemic fungal infection.